NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Core Insights - NuCana plc presented new clinical data for NUC-7738 at the ESMO Immuno-Oncology Congress 2025, highlighting its effectiveness in treating PD-1 inhibitor-resistant metastatic melanoma [1][2][4] Clinical Data Summary - The combination of NUC-7738 and pembrolizumab showed clinical activity with two partial responses and seven cases of stable disease, including one case converting to a complete metabolic response [2][3] - A total of nine patients have been treated in the Expansion Cohort, with plans to enroll up to 28 additional patients, bringing the total to 40 [3] - No new safety signals were reported, and several patients continue to show ongoing disease control [3] Company Statements - The CEO of NuCana expressed satisfaction with the study's progress, emphasizing the potential benefits of NUC-7738 for patients with advanced melanoma [4] - The findings support continued enrollment and advancement towards a potential registrational pathway for NUC-7738 [4] Presentation Details - The presentation at the ESMO Congress included an abstract titled "A Phase 2 expansion study of NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant cutaneous melanoma" [5] - The poster number for the presentation was 321TiP, and it was presented by Dr. Miranda J. Payne [5] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology [6][7] - The company's pipeline includes NUC-7738, which targets multiple aspects of the tumor microenvironment, and NUC-3373, derived from the chemotherapy agent 5-fluorouracil [7]